Limits...
Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease

View Article: PubMed Central - PubMed

ABSTRACT

Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting, sustained drug release, and decreased adverse effects. Here, we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition, the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment.

No MeSH data available.


Schematic illustration of cell-specific drug delivery by nanotherapeutics after oral administration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016370&req=5

Figure 2: Schematic illustration of cell-specific drug delivery by nanotherapeutics after oral administration.

Mentions: To further reduce side effects and increase the drug concentration at inflamed sites, researchers have sought to induce active targeting[53]. The interactions between targeting ligands on the NPs surface and specific receptors over-expressed at inflamed sites are expected to improve the bioadhesion and the internalization of NPs to specific cells. Various ligand-mediated targeted drug delivery systems are compared in Table 1, and their targeted drug delivery process is shown in Figure 2.


Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease
Schematic illustration of cell-specific drug delivery by nanotherapeutics after oral administration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016370&req=5

Figure 2: Schematic illustration of cell-specific drug delivery by nanotherapeutics after oral administration.
Mentions: To further reduce side effects and increase the drug concentration at inflamed sites, researchers have sought to induce active targeting[53]. The interactions between targeting ligands on the NPs surface and specific receptors over-expressed at inflamed sites are expected to improve the bioadhesion and the internalization of NPs to specific cells. Various ligand-mediated targeted drug delivery systems are compared in Table 1, and their targeted drug delivery process is shown in Figure 2.

View Article: PubMed Central - PubMed

ABSTRACT

Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting, sustained drug release, and decreased adverse effects. Here, we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition, the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment.

No MeSH data available.